InsiderClue
← All stocks

Generate Biomedicines, Inc.

GENB Net buying
CIK 0002100782 #2030 in the set updated 17 Sep 2026
Bought (12 mo)
$150.30M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$16.00K
$16.00K on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 1 sales
Net
+$150.28M
+$150.30M against sales at will

By person

7 insiders · 13 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
AFEYAN NOUBAR
Director
$150.00M (6)
—
+$150.00M
1,562,500
1.22%
$25.00M
—
Nally Michael
Chief Executive Officer
$240.00K (1)
—
+$240.00K
1,889,361
1.47%
$30.23M
+56.0%
Silvers Jason
President & CFO
$32.00K (3)
—
+$32.00K
1,000
0.0008%
$16.00K
—
Mendillo Jane L
Director
$24.00K (1)
—
+$24.00K
1,500
0.0012%
$24.00K
—
ARNOLD FRANCES
Director
—
$16.00K (1) scheduled
−$16.00K
463,944
0.3615%
$7.42M
−0.2%
Grous Beth
Chief People Officer
$4.80K (1)
—
+$4.80K
300
0.0002%
$4.80K
—
Bancel Stephane
Director
—
—
—
724,160
0.5642%
$11.59M
—

Individual transactions

12
Insider
Date
Role
Action
Shares
Price
Amount
Nally Michael
4 Mar 2026
Chief Executive Officer
Buy
20,000
$12.00
$240.00K
AFEYAN NOUBAR
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
AFEYAN NOUBAR
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
AFEYAN NOUBAR
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Mendillo Jane L
2 Mar 2026
Director
Buy
1,500
$16.00
$24.00K
AFEYAN NOUBAR
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
AFEYAN NOUBAR
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
AFEYAN NOUBAR
2 Mar 2026
Director
Buy indirect
1,562,500
$16.00
$25.00M
Silvers Jason
2 Mar 2026
President & CFO
Buy indirect
1,000
$16.00
$16.00K
Silvers Jason
2 Mar 2026
President & CFO
Buy indirect
500
$16.00
$8.00K
Silvers Jason
2 Mar 2026
President & CFO
Buy indirect
500
$16.00
$8.00K
Grous Beth
2 Mar 2026
Chief People Officer
Buy indirect
300
$16.00
$4.80K
Show all 13 transactions →

What was left out

Form 4 filings counted 17
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 67,320,805
History held since 2 Mar 2026